Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed Hematologic Malignancy: early-phase trial registry
3 of 4 indexed Relapsed Hematologic Malignancy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Relapsed Hematologic Malignancy: 4 US clinical trials tracked, 3 recruiting.
Relapsed Hematologic Malignancy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Joaquina Baranda, running 1 of these trials.
Enrollment posture brief
Registry condition relapsed-hematologic-malignancy
OPEN 3 | RECR 75% | LATE 0 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Relapsed Hematologic Malignancy lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed Hematologic Malignancy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed Hematologic Malignancy is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products
St. Jude Children's Research Hospital
NCT05713214
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis
NCT03328078
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Pack Health
NCT05956457
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
Joaquina Baranda
NCT03560882
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed Hematologic Malignancy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed Hematologic Malignancy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed Hematologic Malignancy page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Relapsed Hematologic Malignancy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Joaquina Baranda sponsors the most Relapsed Hematologic Malignancy trials on record, review their full trial history before evaluating a specific study. See Joaquina Baranda's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed Hematologic Malignancy condition card totals 4 registered trials; most-linked intervention Digital Health Coaching Program; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.